ST. PAUL, Minn., Oct. 24 /PRNewswire/ -- Debacterol, a topical
treatment that, with a single application, completely stops the pain of canker sores in just five seconds and dramatically speeds the sores' healing, will soon be available for sale to consumers, according to Northern Research Laboratories, the product's manufacturer.
Debacterol was recently recognized as a pre-amendment drug under the Code of Federal Regulations by the U.S. Food and Drug Administration (FDA).
This FDA recognition opens the door for Debacterol, previously a
"grandfathered" product, to be sold to the general public, said Reg Dupre, CEO and President of Northern Research Laboratories.
Debacterol has previously only been available to consumers through dentists and other health care professionals. During the past eight months, more than 350,000 treatments of Debacterol have been distributed to more than 50,000 U.S. health care professionals. Northern Research Laboratories reports no returns for product failure. Debacterol is now available by prescription.
"Debacterol's quick relief from canker sore pain will be welcomed by
millions of people," said Dupre. The U.S. Surgeon General reports that an estimated one in five Americans experience periodic canker sores. Left untreated, the oral lesions can cause extreme pain and take as long as 14 to 16 days to heal.
Debacterol is the only canker sore treatment available that
chemically cauterizes the oral lesion in just ONE treatment, eliminating pain associated with the lesion without harming healthy surrounding tissue. A single application of Debacterol with a cotton swab has been found to stop canker sore pain in just five seconds.
Healing time of the lesion is reduced as well. A clinical study
conducted by the University of Minnesota School of Dentistry found that more than 70 percent of the lesions treated with Debacterol had complete healing by day six, compared with other treatments, which needed more than 10-16 days for complete healing.
Unlike other canker sore treatments sold today, Debacterol's unique
therapeutic chemical agents penetrate and cauterize the affected area.
This results in a denaturing of infected tissues, which, in turn, allows
epithelial cells (healthy tissue cells) to begin immediate regeneration.
Two recent independent dental research organizations evaluated
Debacterol's effectiveness in the treatment of canker sores in more than 400 private clinical trials. Debacterol scored high in all categories.
Reprints of these studies are available by contacting Northern Research Laboratories at 4225 White Bear Parkway, Suite 600, St. Paul, Minn. 55110 or by calling 651-653-3380.
Northern Research Laboratories recently consolidated its
manufacturing, packaging and laboratory operations in a new production and research center in the suburban St. Paul, Minn., community of White Bear Lake.
SOURCE Northern Research Laboratories, Inc.
-0- 10/24/2001
/CONTACT: Reg Dupre, CEO, President of Northern Research
Laboratories,
Inc., +1-651-653-3380, [email protected] /
